SCHEMBL474535

SCHEMBL474535

CC(C)(C)c1ccc(-c2csc(N)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.59
RAB9A P51151 7/20 0.59
LTA4H P09960 7/20 0.59
NPC1 O15118 6/20 0.59
MAPT P10636 5/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
KDM4E B2RXH2 4/20 0.59
NFKB1 P19838 2/20 0.59
NFKB2 Q00653 2/20 0.59
RELA Q04206 2/20 0.59
MEN1 O00255 1/20 0.59
LMNA P02545 1/20 0.59
KMT2A Q03164 1/20 0.59
MKNK1 Q9BUB5 1/20 0.59
MKNK2 Q9HBH9 1/20 0.59
ALOX5 P09917 1/20 0.59
POLB P06746 1/20 0.59
MAPK1 P28482 1/20 0.55
CYP3A4 P08684 1/20 0.55
NOS1 P29475 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484808 0.86 LTA4H (0.61) ALDH1A1RAB9ALTA4HNPC1MAPT
SCHEMBL1771825 0.84 ALDH1A1 (0.79) ALDH1A1RAB9ALTA4HNPC1MAPT
SCHEMBL23610361 0.82 ALDH1A1 (0.83) ALDH1A1RAB9ALTA4HNPC1MAPT
SCHEMBL12203573 0.81 MAPT (0.58) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL474291 0.81 LTA4H (0.82) ALDH1A1RAB9ALTA4HNPC1MAPT
SCHEMBL4333577 0.81 MAPT (0.53) ALDH1A1RAB9ALTA4HNPC1MAPT
SCHEMBL14755554 0.80 CCR4 (0.48) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL3798038 0.80 ALDH1A1 (0.59) ALDH1A1RAB9ALTA4HNPC1MAPT
SCHEMBL231094 0.79 LTA4H (0.80) ALDH1A1RAB9ALTA4HNPC1MAPT
SCHEMBL172279 0.78 ALDH1A1 (0.70) ALDH1A1RAB9ALTA4HNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
US-20210299131-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH NATIONAL INSTITUTES OF HEALTH 2021-09-30 US disclosed
US-10953017-B2 Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such SOUTHERN RESEARCH INSTITUTE (US) 2021-03-23 US disclosed
US-7595398-B2 N-(5-membered aromatic ring)-amido anti-viral compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-29 US disclosed
EP-1971597-A2 N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 2008-09-24 EP disclosed
US-20070265265-A1 N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. 2007-11-15 US disclosed
WO-2007070600-A2 N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 2007-06-21 WO disclosed
WO-2005005382-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2005-01-20 WO disclosed
EP-0259972-B1 HETEROCYCLIC PROPENE AMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS LILLY INDUSTRIES LIMITED (GB) 1993-07-14 EP disclosed
US-4983619-A Leukotriene antagonists LILLY INDUSTRIES LIMITED (GB) 1991-01-08 US disclosed
EP-0259972-A2 Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals LILLY INDUSTRIES LIMITED (GB) 1988-03-16 EP disclosed
US-4407810-A TREATMENT OF ALLERGIC DISORDERS BASF AKTIENGESELLSCHAFT (DE) 1983-10-04 US disclosed
EP-0044442-A1 N-(4-Phenyl-2-thiazolyl)-oxamidic-acid-2-ethoxyethylester, process for its preparation and pharmaceutical compositions containing this compound BASF Aktiengesellschaft (DE) 1982-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 ALDH1A1 2267/4885RAB9A 2879/4885LTA4H 3228/4885
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 ALDH1A1 1635/4885RAB9A 2621/4885LTA4H 3460/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 ALDH1A1 2267/4885RAB9A 2879/4885LTA4H 3228/4885
US-20210299131-A1 TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH NFKBIA, NFRKB, TFEB ALDH1A1 1729/4885RAB9A 2402/4885LTA4H 207/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 ALDH1A1 1635/4885RAB9A 2621/4885LTA4H 3460/4885
US-20070265265-A1 N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS ZC3HAV1, ZC3HAV1L, HAVCR2 ALDH1A1 4423/4885RAB9A 487/4885LTA4H 4415/4885
US-10953017-B2 Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such NFKBIA, NFRKB, TFEB ALDH1A1 1729/4885RAB9A 2402/4885LTA4H 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.